[Hormone therapy and breast cancer]

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Nuclear estrogen receptors (ER) are primary targets for treating hormone-dependent breast cancers.
• Current endocrine therapies include selective estrogen receptor modulators (SERM), selective estrogen receptor downregulators (SERD), and aromatase inhibitors.
• While effective, resistance to these treatments is a significant clinical challenge.

Purpose of the Study:

• To elucidate the mechanisms of action for endocrine therapies targeting ER in breast cancer.
• To understand the determinants of de novo and acquired resistance to these treatments.
• To correlate treatment mechanisms with the occurrence of adverse side effects.

Main Methods:

• Review of existing literature on ER-targeted endocrine therapies.
• Analysis of clinical data on treatment efficacy and resistance patterns.
• Pharmacological and molecular mechanisms of SERMs, SERDs, and aromatase inhibitors were examined.

Main Results:

• Endocrine therapies function by competitively inhibiting estrogen or blocking its synthesis.
• Resistance can arise through various mechanisms, impacting treatment effectiveness.
• Different classes of endocrine agents are associated with distinct side effect profiles.

Conclusions:

• A deeper understanding of ER-targeting drug mechanisms is essential for overcoming treatment resistance.
• Knowledge of mechanisms can guide the development of more effective therapies and personalized treatment strategies.
• Further research into treatment mechanisms may help predict and mitigate adverse effects.